Malignant peripheral nerve sheath tumors

Neurosurgery Clinics of North America

Volumn 15, Issue 2, 2004, Pages 203-216

  Perrin, Richard G ^a   Guha, Abhijit ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; IFOSFAMIDE; IMATINIB; NEUROFIBROMIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; THALIDOMIDE;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CHROMOSOME 17Q; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MULTIMODALITY CANCER THERAPY; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PERIPHERAL NERVE TUMOR; PHYSICAL EXAMINATION; PHYSIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PSYCHOTHERAPY; RADIODIAGNOSIS; REVIEW; RISK FACTOR; SOFT TISSUE SARCOMA; WORLD HEALTH ORGANIZATION;

HUMANS; MAGNETIC RESONANCE IMAGING; NEUROFIBROMATOSIS 1; PERIPHERAL NERVOUS SYSTEM NEOPLASMS;

EID: 2942585312     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2004.02.004     Document Type: Review

References (125)

1. Kleihues P., Cavenee W.K. International Academy of Pathology, International Society of Neuropathology, Preuss Foundation for Brain Tumor Research. Pathology and genetics of tumours of the nervous system. 2nd edition:2000;IARC Press, Lyon
2. Ducatman B.S., Scheithauer B.W., Piepgras D.G., Reiman H.M., Ilstrup D.M. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 57:(10):1986;2006-2021
3. Hruban R.H., Shiu M.H., Senie R.T., Woodruff J.M. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer. 66:(6):1990;1253-1265
4. Collin C., Godbold J., Hajdu S., Brennan M. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol. 5:(4):1987;601-612
5. Russell W.O., Cohen J., Enzinger F., et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer. 40:(4):1977;1562-1570
6. Ramanathan R.C., Thomas J.M. Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis. Eur J Surg Oncol. 25:(2):1999;190-193
7. Sorensen S.A., Mulvihill J.J., Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 314:(16):1986;1010-1015
8. McGaughran J., Harris D.I., Donnai D., Teare D., McLeod R., Kingston H., et al. A clinical study of type 1 neurofibromatosis in North West England. J Med Genet. 36:1999;197-203
9. Kourea H.P., Bilsky M.H., Leung D.H., Lewis J.J., Woodruff J.M. Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. Cancer. 82:(11):1998;2191-2203
10. Birch R. Peripheral nerve tumors. Dyck P.J., Thomas R.K. Peripheral nerve tumors. 1993;1623-1640 WB Saunders, Philadelphia
11. Enneking W. Musculo-skeletal tumor surgery. 1983;Churchill Livingstone, Edinburgh
12. Woodruff J.M., Selig A.M., Crowley K., Allen P.W. Schwannoma (neurilemoma) with malignant transformation. A rare, distinctive peripheral nerve tumor. Am J Surg Pathol. 18:(9):1994;882-895
13. Drago G., Pasquier B., Pasquier D., et al. Malignant peripheral nerve sheath tumor arising in a "de novo" ganglioneuroma: a case report and review of the literature. Med Pediatr Oncol. 28:(3):1997;216-222
14. Ricci A. Jr., Parham D.M., Woodruff J.M., Callihan T., Green A., Erlandson R.A. Malignant peripheral nerve sheath tumors arising from ganglioneuromas. Am J Surg Pathol. 8:(1):1984;19-29
15. Sakaguchi N., Sano K., Ito M., Baba T., Fukuzawa M., Hotchi M. A case of von Recklinghausen's disease with bilateral pheochromocytoma - malignant peripheral nerve sheath tumors of the adrenal and gastrointestinal autonomic nerve tumors. Am J Surg Pathol. 20:(7):1996;889-897
16. Ducatman B.S., Scheithauer B.W. Postirradiation neurofibrosarcoma. Cancer. 51:(6):1983;1028-1033
17. Foley K.M., Woodruff J.M., Ellis F.T., Posner J.B. Radiation-induced malignant and atypical peripheral nerve sheath tumors. Ann Neurol. 7:(4):1980;311-318
18. Cerofolini E., Landi A., DeSantis G., Maiorana A., Canossi G., Romagnoli R. MR of benign peripheral nerve sheath tumors. J Comput Assist Tomogr. 15:(4):1991;593-597
19. Levine E., Huntrakoon M., Wetzel L.H. Malignant nerve-sheath neoplasms in neurofibromatosis: distinction from benign tumors by using imaging techniques. AJR Am J Roentgenol. 149:(5):1987;1059-1064
20. Stull M.A., Moser R.P. Jr., Kransdorf M.J., Bogumill G.P., Nelson M.C. Magnetic resonance appearance of peripheral nerve sheath tumors. Skeletal Radiol. 20:(1):1991;9-14
21. Suh J.S., Abenoza P., Galloway H.R., Everson L.I., Griffiths H.J. Peripheral (extracranial) nerve tumors: correlation of MR imaging and histologic findings. Radiology. 183:(2):1992;341-346
22. Strauss L.G., Conti P.S. The applications of PET in clinical oncology. J Nucl Med. 32:1991;623-648
23. Kern K.A., Brunetti A., Norton J.A., Chang A.E., Malawer M., Lack E., et al. Metabolic imaging of human extremity musculoskeletal tumours by PET. J Nucl Med. 29:1988;181-186
24. Adler L.P., Blair H.F., Makley J.T., Williams R.P., Joyce M.J., Leisure G., et al. Noninvasive grading of musculoskeletal tumours using PET. J Nucl Med. 32:1991;1508-1512
25. Lucas J.D., O'Doherty M.J., Wong J.C.H., Bingham J.B., McKee P.H., Fletcher C.D.M., et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft tissue sarcomas. J Bone Joint Surg Br. 80:1998;441-447
26. 18fluorodeoxyglucose positron emission tomography in the detection of malignant peripheral nerve sheath tumors in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 68:2000;353-357
27. Benign and malignant tumors of peripheral nerves. Enzinger F.M., Weiss S.W. Soft tissue tumors. 3rd edition:1995;829-863 Mosby-Year Book, St. Louis
28. Masson P. Recklinghausen's neurofibromatosis. Sensory neuromas and motor neuromas, Libman Anniversary. vol. 2:1932;International Press, New York. p. 793-802
29. Woodruff J.M., Horten B.C., Erlandson R.A. Pathology of peripheral nerves and paragangliomas. Silverberg S.G. Principles and practice of surgical pathology. 1983;1509-1515 Wiley, New York
30. Ducatman B.S., Scheithauer B.W. Malignant peripheral nerve sheath tumors with divergent differentiation. Cancer. 54:1984;1049-1057
31. Pisters P.W., Leung D.H., Woodruff J., Shi W., Brennan M.F. Analysis of prognostic factors in 1, 041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 14:(5):1996;1679-1689
32. Sadoski C., Suit H.D., Rosenberg A., Mankin H., Efird J. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol. 52:(4):1993;223-230
33. Bell R.S., O'Sullivan B., Liu F.F., et al. The surgical margin in soft-tissue sarcoma. J Bone Joint Surg Am. 71:(3):1989;370-375
34. Santoro A., Tursz T., Mouridsen H., Verveij J., Steward W., Somers R., et al. Doxorubicin versus CYVADIC verses doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 13:1995;1537-1545
35. Santoro A. Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide? Ann Oncol. 10:1999;151-154
36. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma in adults: meta-analysis of individual data. Lancet. 350:1997;1647-1654
37. Angelov L., Davis A., O'Sullivan B., Bell R., Guha A. Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery. 43:(1):1998;56-64. discussion 64-5
38. Angelov L., Feldkamp M., Guha A. Operative neurosurgery. Kaye A.H., Black P.McL. Management of peripheral nerve tumors. 2000;2155-2167 Churchill Livingstone, New York
39. Angelov L., Guha A. Essentials of neurooncology. Bernstein M., Berger M. Peripheral nerve tumors. 2000;434-444 Thieme Medical, New York
40. Angelov L., Salhia B., Roncari L., Guha A. Inhibition of angiogenesis by blocking activation of the VEGFR-2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 59:1999;5536-5541
41. Ferner R., Gutmann D., Coffin C., Grimer R., Guha A., Judson I., et al. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Res. 62:2002;1573-1577
42. von Recklinghausen F.D. Über die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. 1882;Hirschwald, Berlin
43. Lott I.T., Richardson E.P. Jr. Neuropathological findings and the biology of neurofibromatosis. Adv Neurol. 29:1981;23-32
44. Gutmann D.H., Collins F.S. von Recklinghausen neurofibromatosis. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. von Recklinghausen neurofibromatosis. 1995;677-696 McGraw-Hill, New York
45. Huson S. Neurofibromatosis 1: a clinical and genetic overview. Huson S.M., Hughes R.A.C. Neurofibromatosis 1: a clinical and genetic overview. 1994;160-203 Chapman and Hall, London
46. Riccardi V.M., Eichner J.E. Neurofibromatosis: phenotype, natural history, and pathogenesis. 1992;Johns Hopkins University Press, Baltimore
47. Trofatter J.A., MacCollin M.M., Rutter J.L., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 72:(5):1993;791-800
48. Rouleau G.A., Merel P., Lutchman M., et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 363:(6429):1993;515-521
49. Evans D.G., Huson S.M., Donnai D., et al. A clinical study of type 2 neurofibromatosis. Q J Med. 84:(304):1992;603-618
50. Stumpf D.A., Alksne J.F., Annegers J.F., Brown S.S., Conneally P.M., Housman D. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 45:(5):1988;575-578
51. Mulvihill J.J., Parry D.M., Sherman J.L., Pikus A., Kaiser-Kupfer M.I., Eldridge R. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med. 113:(1):1990;39-52
52. Grifa A., Piemontese M.R., Melchionda S., et al. Screening of neurofibromatosis type 1 gene: identification of a large deletion and of an intronic variant. Clin Genet. 47:(6):1995;281-284
53. Zoller M., Rembeck B., Akesson H.O., Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm Venereol. 75:(2):1995;136-140
54. Riccardi V.M. von Recklinghausen neurofibromatosis. N Engl J Med. 305:(27):1981;1617-1627
55. Shannon K.M., O'Connell P., Martin G.A., et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 330:(9):1994;597-601
56. Mulvihill J.J. Malignancy: epidemiologically associated cancers. Huson S.M., Hughes R.A.C. Malignancy: epidemiologically associated cancers. 1994;305-315 Chapman and Hall, London
57. Preiser S.A., Davenport C.B. Multiple neurofibromatosis (Von Recklinghausens disease) and its inheritance. Am J Med Sci. 156:1918;507
58. Crowe F. A clinical, pathological and genetic study of multiple neurofibromatosis. 1956;CC Thomas, Springfield
59. Borberg A. Clinical and genetic investigations into tuberous sclerosis and Recklinghausen's neurofibromatosis; contribution to elucidation of interrelationship and agenics of the syndromes. Acta Neurol Scand Suppl. 71:1951;1-239
60. Marchuk D.A., Saulino A.M., Tavakkol R., et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 11:(4):1991;931-940
61. Sergeyev A.S. On the mutation rate of neurofibromatosis. Humangenetik. 28:(2):1975;129-138
62. Carey J.C., Baty B.J., Johnson J.P., Morrison T., Skolnick M., Kivlin J. The genetic aspects of neurofibromatosis. Ann NY Acad Sci. 486:1986;45-56
63. Richards F.M., Payne S.J., Zbar B., Affara N.A., Ferguson-Smith M.A., Maher E.R. Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet. 4:(11):1995;2139-2143
64. Rodenhiser D.I., Coulter-Mackie M.B., Singh S.M. Evidence of DNA methylation in the neurofibromatosis type 1 (NF1) gene region of 17q11.2. Hum Mol Genet. 2:(4):1993;439-444
65. Colman S.D., Williams C.A., Wallace M.R. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet. 11:(1):1995;90-92
66. Jadayel D., Fain P., Upadhyaya M., et al. Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature. 343:(6258):1990;558- 559
67. Hall J.G. Genomic imprinting: review and relevance to human diseases. Am J Hum Genet. 46:(5):1990;857-873
68. Stephens K., Kayes L., Riccardi V.M., Rising M., Sybert V.P., Pagon R.A. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet. 88:(3):1992;279-282
69. Easton D.F., Ponder M.A., Huson S.M., Ponder B.A. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 53:(2):1993;305-313
70. Hofman K.J., Boehm C.D. Familial neurofibromatosis type 1: clinical experience with DNA testing. J Pediatr. 120:(3):1992;394-398
71. Dublin S., Riccardi V.M., Stephens K. Methods for rapid detection of a recurrent nonsense mutation and documentation of phenotypic features in neurofibromatosis type 1 patients. Hum Mutat. 5:(1):1995;81-85
72. Gasparini P., D'Agruma L., Pio de Cillis G., Balestrazzi P., Mingarelli R., Zelante L. Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP: identification of three novel mutations and of two new polymorphisms. Hum Genet. 97:(4):1996;492-495
73. Knudson A.G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 68:(4):1971;820-823
74. Guha A., Lau N., Huvar I., et al. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene. 12:(3):1996;507-513
75. Feldkamp M.M., Lau N., Provias J.P., Gutmann D.H., Guha A. Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: a pathological and molecular explanation. Case report. J Neurosurg. 84:(5):1996;867-873
76. Takahashi K., Suzuki H., Hatori M., et al. Reduced expression of neurofibromin in the soft tissue tumours obtained from patients with neurofibromatosis type I. Clin Sci (Lond). 88:(5):1995;581-585
77. Legius E., Marchuk D.A., Collins F.S., Glover T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet. 3:(2):1993;122-126
78. Viskochil D., Buchberg A.M., Xu G., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 62:(1):1990;187-192
79. Wallace M.R., Marchuk D.A., Andersen L.B., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 249:(4965):1990;181-186
80. Li Y., O'Connell P., Breidenbach H.H., et al. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics. 25:(1):1995;9-18
81. Xu G.F., O'Connell P., Viskochil D., et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 62:(3):1990;599-608
82. Viskochil D., White R., Cawthon R. The neurofibromatosis type 1 gene. Annu Rev Neurosci. 16:1993;183-205
83. DeClue J.E., Cohen B.D., Lowy D.R. Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci USA. 88:(22):1991;9914-9918
84. Gutmann D.H., Wood D.L., Collins F.S. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA. 88:(21):1991;9658-9662
85. Daston M.M., Scrable H., Nordlund M., Sturbaum A.K., Nissen L.M., Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron. 8:(3):1992;415-428
86. Gutmann D.H., Geist R.T., Wright D.E., Snider W.D. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ. 6:(3):1995;315-323
87. Buchberg A.M., Cleveland L.S., Jenkins N.A., Copeland N.G. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the Ras cyclic AMP pathway. Nature. 347:(6290):1990;291-294
88. Ahmadian M.R., Wiesmuller L., Lautwein A., Bischoff F.R., Wittinghofer A. Structural differences in the minimal catalytic domains of the GTPase-activating proteins p120GAP and neurofibromin. J Biol Chem. 271:(27):1996;16409-16415
89. Bollag G., McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature. 351:(6327):1991;576-579
90. McCormick F. Ras signaling and NF1. Curr Opin Genet Dev. 5:(1):1995;51-55
91. Downward J. Regulation of p21ras by GTPase activating proteins and guanine nucleotide exchange proteins. Curr Opin Genet Dev. 2:(1):1992;13-18
92. Downward J. Regulatory mechanisms for ras proteins. Bioessays. 14:(3):1992;177-184
93. Rozakis-Adcock M., Fernley R., Wade J., Pawson T., Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature. 363:(6424):1993;83-85
94. Lowenstein E.J., Daly R.J., Batzer A.G., et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 70:(3):1992;431-442
95. Buday L., Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell. 73:(3):1993;611-620
96. Chardin P., Camonis J.H., Gale N.W., et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science. 260:(5112):1993;1338-1343
97. Egan S.E., Giddings B.W., Brooks M.W., Buday L., Sizeland A.M., Weinberg R.A. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature. 363:(6424):1993;45-51
98. McCormick F. Signal transduction. How receptors turn Ras on. Nature. 363:(6424):1993;15-16
99. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:(17):1989;4682-4689
100. Cantley L.C., Auger K.R., Carpenter C., et al. Oncogenes and signal transduction. Cell. 64:(2):1991;281-302
101. Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 356:(6371):1992;713-715
102. DeClue J.E., Papageorge A.G., Fletcher J.A., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 69:(2):1992;265-273
103. Sherman L.S., Atit R., Rosenbaum T., Cox A.D., Ratner N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem. 275:2000;30740-30745
104. Johnson M.R., DeClue J.E., Felzmann S., et al. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol. 14:(1):1994;641-645
105. Gregory P.E., Gutmann D.H., Mitchell A., et al. Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet. 19:(3):1993;265-274
106. Bollag G., McCormick F., Clark R. Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. Embo J. 12:(5):1993;1923-1927
107. Jhanwar S.C., Chen Q., Li F.P., Brennan M.F., Woodruff J.M. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet. 78:(2):1994;138-144
108. Ottini L., Esposito D.L., Richetta A., et al. Alterations of microsatellites in neurofibromas of von Recklinghausen's disease. Cancer Res. 55:(23):1995;5677-5680
109. Uchida T., Wang C., Wada C., Iwamura M., Egawa S., Koshiba K. Microsatellite instability in transitional cell carcinoma of the urinary tract and its relationship to clinicopathological variables and smoking. Int J Cancer. 69:(2):1996;142-145
110. Zhu J., Guo S.Z., Beggs A.H., et al. Microsatellite instability analysis of primary human brain tumors. Oncogene. 12:(7):1996;1417-1423
111. Castresana J.S., Barrios C., Gomez L., Kreicbergs A. No association between c-myc amplification and TP53 mutation in sarcoma tumorigenesis. Cancer Genet Cytogenet. 76:(1):1994;47-49
112. Andreassen A., Oyjord T., Hovig E., et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 53:(3):1993;468-471
113. Lothe R.A., Slettan A., Saeter G., Brogger A., Borresen A.L., Nesland J.M. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J Neuropathol Exp Neurol. 54:(1):1995;65-73
114. Cordon-Cardo C., Latres E., Drobnjak M., et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:(3):1994;794-799
115. Legius E., Dierick H., Wu R., et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer. 10:(4):1994;250-255
116. Menon A.G., Anderson K.M., Riccardi V.M., et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA. 87:(14):1990;5435-5439
117. Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 286:1999;2172-2176
118. Vogel K.S., Klesse L.J., Velasco-Miguel S., Meyers K., Rushing E.J., Parada L.F. Mouse tumor model for neurofibromatosis 1. Science. 286:1999;2176-2179
119. Nielsen G.P., Stemmer-Rachamimov A.O., Ino Y., Moller M.B., Rosenberg A.E., Louis D.N. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 155:1999;1879-1884
120. kip in malignant transformation of neurofibromas. Am J Pathol. 155:1999;1885-1891
121. Perosio P.M., Brooks J.J. Expression of growth factors and growth factor receptors in soft tissue tumors. Implications for the autocrine hypothesis. Lab Invest. 60:1989;245-253
122. Hirota S., Nomura S., Asada H., Ito A., Morii E., Kitamura Y. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med. 117:1993;996-999
123. Arbiser J.L., Flynn E., Barbhill R.L. Analysis of vascularity of human neurofibromas. J Acad Dermatol. 36:1998;950-954
124. Badache A., DeVries G.H. Neurofibroma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol. 177:1998;334-342
125. DeClue J.E., Heffelfinger S., Benvenuto G., Ling B., Li S., Rui W., et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest. 105:2000;1233-1241